Antibodies against aberrant glycans as cancer biomarkers

Blšáková, Anna; Kveton, Filip; Kasák, Peter; Tkáč, Ján

doi:10.1080/14737159.2020.1687295

Cited by 11 publications

(10 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell-surface glycans have been implicated in tumour aggressiveness, metastasis and chemoresistance, 14 , 15 and their presence can be targeted by therapeutic agents, as well as being used for diagnostic purposes; for example, the carbohydrate antigens CA19-9, CA125 and CA15-3 are used for pancreatic, ovarian and breast cancer detection, respectively. 16 – 19 …”

Section: Introductionmentioning

confidence: 99%

Insights into the role of sialylation in cancer progression and metastasis

2020

View full text Add to dashboard Cite

Upregulation of sialyltransferases—the enzymes responsible for the addition of sialic acid to growing glycoconjugate chains—and the resultant hypersialylation of up to 40–60% of tumour cell surfaces are established hallmarks of several cancers, including lung, breast, ovarian, pancreatic and prostate cancer. Hypersialylation promotes tumour metastasis by several routes, including enhancing immune evasion and tumour cell survival, and stimulating tumour invasion and migration. The critical role of enzymes that regulate sialic acid in tumour cell growth and metastasis points towards targeting sialylation as a potential new anti-metastatic cancer treatment strategy. Herein, we explore insights into the mechanisms by which hypersialylation plays a role in promoting metastasis, and explore the current state of sialyltransferase inhibitor development.

show abstract

Section: Introductionmentioning

confidence: 99%

Insights into the role of sialylation in cancer progression and metastasis

2020

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, over the past decades, many works on diagnostic and predictive studies of TAGs have been published [13][14][15]. Glycan-specific antibodies are also represented in the literature as potential biomarkers for cancer diagnosis [16,17]. However, the relationship between AG Abs and prognosis of cancer patients remains poorly understood.…”

Section: Association Of the Level Of Ag Abs With Survivalmentioning

confidence: 99%

Prospects and Challenges of the Study of Anti-Glycan Antibodies and Microbiota for the Monitoring of Gastrointestinal Cancer

Smorodin

2021

IJMS

View full text Add to dashboard Cite

Over the past decades, a large amount of data has been accumulated in various subfields of glycobiology. However, much clinically relevant data and many tools are still not widely used in medicine. Synthetic glycoconjugates with the known structure of glycans are an accurate tool for the study of glycan-binding proteins. We used polyacrylamide glycoconjugates (PGs) including PGs with tumour-associated glycans (TAGs) in immunoassays to assess the prognostic potential of the serum level of anti-glycan antibodies (AG Abs) in gastrointestinal cancer patients and found an association of AG Abs with survival. The specificity of affinity-isolated AG Abs was investigated using synthetic and natural glycoconjugates. AG Abs showed mainly a low specificity to tumour-associated and tumour-derived mucins; therefore, the protective role of the examined circulating AG Abs against cancer remains a challenge. In this review, our findings are analysed and discussed in the context of the contribution of bacteria to the AG Abs stimulus and cancer progression. Examples of the influence of pathogenic bacteria colonising tumours on cancer progression and patient survival through mechanisms of interaction with tumours and dysregulated immune response are considered. The possibilities and problems of the integrative study of AG Abs and the microbiome using high-performance technologies are discussed.

show abstract

“…Around 1% of human genes undergo glycosylation, a posttranslational modification where carbohydrates are linked to proteins via glycosidic bonds with the aid of enzymes (glycotransferases; ref. 62). When the activity of these enzymes is compromised, it results in the synthesis of aberrant glycans responsible for many diseases including cancer.…”

Section: Glycan Arraysmentioning

confidence: 99%

Autoantibodies in Early Detection of Breast Cancer

Rauf

Anderson

LaBaer

2020

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

In spite of the progress made in treatment and early diagnosis, breast cancer remains a major public health issue worldwide. Although modern image-based screening modalities have significantly improved early diagnosis, around 15% to 20% of breast cancers still go undetected. In underdeveloped countries, lack of resources and cost concerns prevent implementing mammography for routine screening. Noninvasive, low-cost, blood-based markers for early breast cancer diagnosis would be an invaluable alternative that would complement mammography screening. Tumor-specific autoantibodies are excellent biosensors that could be exploited to monitor disease-specific changes years before disease onset. Although clinically informative autoantibody markers for early breast cancer screening have yet to emerge, progress has been made in the development of tools to discover and validate promising autoantibody signatures. This review focuses on the current progress toward the development of autoantibody-based early screening markers for breast cancer.See all articles in this CEBP Focus section, "NCI

show abstract

Antibodies against aberrant glycans as cancer biomarkers

Cited by 11 publications

References 98 publications

Insights into the role of sialylation in cancer progression and metastasis

Insights into the role of sialylation in cancer progression and metastasis

Prospects and Challenges of the Study of Anti-Glycan Antibodies and Microbiota for the Monitoring of Gastrointestinal Cancer

Autoantibodies in Early Detection of Breast Cancer

Contact Info

Product

Resources

About